Annovis Bio Inc.

Contributing Author

Recent Articles by Annovis Bio Inc.

May-26	Annovis Bio Regains NYSE Listing Compliance ANVS -7.62% GlobeNewswire
May-20	Annovis Announces Pricing of $15.0 Million Public Offering of Common Stock and Accompanying Warrants ANVS +5.15% GlobeNewswire
May-19	Annovis Announces Launch of Proposed Public Offering of Common Stock and Accompanying Warrants ANVS -5.37% GlobeNewswire
May-15	Annovis Provides Corporate Updates and Reports First Quarter 2026 Financial Results ANVS GlobeNewswire
May-07	Annovis CEO to Present on Multi-Protein Model of Alzheimer's Disease at Fierce Biotech Week 2026 ANVS -5.83% GlobeNewswire
Apr-28	Annovis Publishes Phase 2/3 Alzheimer's Trial Results in Nature Portfolio ANVS GlobeNewswire
Apr-10	Annovis Closes $10 Million Offering, Extending Cash Runway Through Phase 3 Alzheimer's Disease 6-Month NDA Submission ANVS GlobeNewswire
Apr-09	Annovis Announces $10 Million Underwritten Offering of Common Stock and Accompanying Warrants ANVS -29.57% GlobeNewswire
Apr-02	Annovis Secures U.S. Patent for Buntanetap in the Prevention and Treatment of Neurological Injuries Caused by Brain Infections ANVS +7.55% GlobeNewswire
Mar-31	Annovis Publishes Historical Review of Buntanetap in The Scientist ANVS +10.95% GlobeNewswire
Mar-19	Annovis Partners with NeuroRPM to Deploy AI-Powered Digital Biomarker Technology in Parkinson's Disease Study ANVS +8.10% GlobeNewswire
Mar-16	Annovis Provides Corporate Updates and Reports Fiscal Year 2025 Financial Results ANVS +12.30% GlobeNewswire
Mar-03	Annovis Announces Two Presentations at the AD/PD 2026 International Conference ANVS GlobeNewswire
Feb-12	Annovis Secures DSMB Approval to Advance Pivotal Phase 3 Trial of Buntanetap in Alzheimer's Disease ANVS GlobeNewswire
Dec-18	Annovis Announces Open-Label Extension Study for Parkinson's Disease Patients ANVS GlobeNewswire
Dec-16	Annovis to Host Corporate Update Webinar on January 28, 2026 ANVS GlobeNewswire
Dec-03	Annovis To Present at the 2025 Annual Meeting of the Parkinson Study Group ANVS +5.44% GlobeNewswire
Nov-24	Annovis Announces Two Presentations at the CTAD 2025 Conference ANVS +7.92% GlobeNewswire
Nov-18	Annovis Announces FDA Meeting to Discuss Parkinson's Disease Dementia Program; Reaffirms FDA Alignment on Pivotal Phase 3 Alzheimer's Disease Study ANVS +11.22% GlobeNewswire
Nov-17	Annovis Reports New Biomarker Data Linking Amyloid Co-Pathology to Accelerated Cognitive Decline in Parkinson's Patients ANVS +29.49% GlobeNewswire
Nov-12	Annovis Provides Corporate Updates and Reports Third Quarter 2025 Financial Results ANVS +15.17% GlobeNewswire
Nov-06	Annovis Achieves Significant Milestones and Sustains Strong Progress in Phase 3 Alzheimer's Program ANVS GlobeNewswire
Oct-27	Annovis Announces $3.4 Million Registered Direct Offering of Common Stock Priced At-the-Market under the NYSE Rules ANVS GlobeNewswire
Oct-15	Annovis Announces Closing of $6 Million Registered Direct Offering of Common Stock ANVS +12.15% ANVS +7.74% GlobeNewswire
Oct-10	Annovis Announces $6 Million Registered Direct Offering of Common Stock ANVS -22.73% GlobeNewswire
Oct-09	Annovis Announces Novel Biomarker Data in Alzheimer's Patients Supporting Buntanetap's Potential as a Disease-Modifying Treatment ANVS GlobeNewswire
Sep-25	Annovis Appoints Mark Guerin as Chief Financial Officer ANVS GlobeNewswire
Sep-16	Annovis Reports Peer-Reviewed Publication Highlighting Pharmacokinetics of Novel Crystal Buntanetap ANVS GlobeNewswire
Sep-02	Annovis to Present at the H.C. Wainwright 27th Annual Global Investment Conference ANVS GlobeNewswire
Aug-12	Annovis Provides Corporate Updates and Reports Second Quarter 2025 Financial Results ANVS GlobeNewswire
Aug-07	Annovis Completes Full Patent Transfer to Crystal Buntanetap ANVS GlobeNewswire
Jun-26	Annovis to Attend the AAIC 2025 with Four Poster Presentations ANVS -5.24% GlobeNewswire
Jun-19	Annovis Announces NYSE Acceptance of Plan to Regain Listing Compliance ANVS GlobeNewswire
Jun-05	Annovis to Host Webinar and Live Q&A on June 24, 2025 ANVS -5.86% GlobeNewswire
May-13	Annovis Provides Corporate Updates and Reports First Quarter 2025 Financial Results ANVS +9.68% GlobeNewswire

Annovis Bio Inc.

Recent Articles by Annovis Bio Inc.

Upgrade your Finviz experience